What is it about?
Dronabinol and cannabidiol (Epidiolex) are components of the cannabis (marijuana) plant. We have demonstrated the pronounced Medicaid prescription distribution patterns of both of the drugs throughout the 50 states including D.C. from 2016-2020.
Featured Image
Photo by manish panghal on Unsplash
Why is it important?
Understanding the prescription distribution patterns of dronabinol and cannabidiol in the US would help guide the healthcare policies and decision making processes of physicians implicated in these cannabinoids.
Perspectives
The marked variation in distribution patterns of dronabinol and cannabidiol throughout the US baffles me because it demonstrates that there is no clear-cut rationale on why certain states have more prescriptions and why some have less relative to their number of Medicaid enrollees. A lot of questions come up, including whether specific state policies might have impacted the prescription patterns or maybe the population in general has varied distributions of individuals suffering from the specific conditions the drugs treat. Since it remains so vague, there is an urge to do further research to figure out the underlying reasons that explain the distributions.
Edward Liu
Geisinger Commonwealth School of Medicine
Read the Original
This page is a summary of: Pronounced State-Level Disparities in Prescription of Cannabinoids to Medicaid Patients, Medical Cannabis and Cannabinoids, June 2023, Karger Publishers,
DOI: 10.1159/000531058.
You can read the full text:
Contributors
The following have contributed to this page
